Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

FDA Updates

The following briefs provide updates on new FDA approvals and indications to help hematology and oncology pharmacists keep up with new information regarding drugs that are coming to market for the management of patients with cancer.
The US Food and Drug Administration (FDA) approved many new cancer drugs and several new indications for previously approved drugs in 2013, as well as the first 2 drugs designated as “breakthrough therapy.”

As many as 1 in 5 cancer patients may experience obstacles in their care, according to a new study published in the Journal of Clinical Oncology. These obstacles include communication issues between patients and their healthcare providers, along with traditional medical errors.

This past Friday, the US Food and Drug Administration (FDA) approved 2 drugs that could help our patients: fentanyl nasal spray (Lazanda, Archimedes Pharma) and rivaroxaban (Xarelto, Janssen Pharmaceuticals).

 

The US Food and Drug Administration (FDA) has approved a short-acting formulation of oxycodone (Oxecta, Pfizer) that uses “Aversion” technology to stop potential abusers from crushing, chewing, snorting, or injecting the drug. Oral abuse remains possible. In addition, Pfizer acknowledged that the potential to abuse the drug through all routes is feasible.

 

The drug is indicated for acute and chronic moderate-to-severe pain.

The US Food and Drug Administration (FDA) has approved a 45 mg for 6-month administration formulation of leuprolide acetate for depot suspension (Lupron Depot, Abbott) for palliative treatment of advanced prostate cancer. This dosing option adds to the existing formulations, which are injected every 1 month, 3 months, and 4 months.

 

The US Food and Drug Administration (FDA) has approved Inform Dual ISH (Ventana Medical Systems), a genetic test that allows for measurement of the number of copies of the HER2 gene in tumor tissue. This method of identification of women with breast cancer who are HER2+ pinpoints who is, and who is not, a candidate for Herceptin (trastuzumab).

 

Page 14 of 14
Results 131 - 138 of 138